(Q61447856)

English

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/I

No description defined

In more languages

Statements

scholarly article

0 references

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/I (English)

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

multidrug-resistant tuberculosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Won-Jung Koh

0 references

author name string

Myungsun Lee

1

0 references

Jeongha Mok

2

0 references

Deog Kyeom Kim

3

0 references

Tae Sun Shim

4

0 references

Doosoo Jeon

6

0 references

Taehoon Lee

7

0 references

Seung Heon Lee

8

0 references

Ju Sang Kim

9

0 references

Jae Seuk Park

10

0 references

Ji Yeon Lee

11

0 references

Song Yee Kim

12

0 references

Jae Ho Lee

13

0 references

Kyung-Wook Jo

14

0 references

Byung Woo Jhun

15

0 references

Young Ae Kang

16

0 references

Joong Hyun Ahn

17

0 references

Chang-Ki Kim

18

0 references

Soyoun Shin

19

0 references

Taeksun Song

20

0 references

Sung Jae Shin

21

0 references

Young Ran Kim

22

0 references

Heejung Ahn

23

0 references

Seokyung Hahn

24

0 references

Ho Jeong Won

25

0 references

Ji Yeon Jang

26

0 references

Sang Nae Cho

27

0 references

Jae-Joon Yim

28

0 references

language of work or name

0 references

publication date

16 January 2019

0 references

0 references

20

0 references

1

0 references

57

0 references

copyright license

Creative Commons Attribution 4.0 International

16 January 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s13063-018-3053-1

0 references

In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delamanid for multidrug-resistant pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in treatment outcomes of multidrug-resistant tuberculosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical Management of Drug-Resistant Tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linezolid for XDR-TB--Final Study Outcomes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical research in the treatment of tuberculosis: current status and future prospects

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea

1 reference

https://pubmed.ncbi.nlm.nih.gov/30651149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13063-018-3053-1

0 references

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s13063-018-3053-1

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61447856&oldid=2000897653"